Pembrolizumab
TAK-676-1003
Phase 1 small_molecule completed
Quick answer
Pembrolizumab for Carcinoma, Non-Small-Cell Lung is a Phase 1 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Carcinoma, Non-Small-Cell Lung
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed